Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Portugal’s life‑science sector generated €29.7 billion ($34.4 billion) in gross value added in 2024, employing over 268,000 people across 124,000 firms. The ecosystem gained visibility after hosting BIO‑Europe Spring, showcasing biotech startups, research parks like Biocant, and major deals such as BioNTech’s acquisition of CellmAbs. Funding remains the biggest obstacle, but the launch of the country’s first life‑science‑focused VC, Biovance Capital, and new government incentives aim to bridge the capital gap. Ongoing projects, including a €38 million ($44 million) gene‑therapy centre and upcoming phase‑2 results from LXbio, signal continued innovation despite financial constraints.
The Confidence Game in Biotech | Ep. 972 https://t.co/RyMgyMVr54 [ 01:12 ] when that trial works [ 01:30 ] manufactured certainty trap [ 02:02 ] linear mental model failure [ 02:33 ] relay race of risk [ 03:31 ] durability risk reality [ 05:29 ] compressing uncertainty...
Biopharma giants Biogen, Eli Lilly and Merck collectively spent over $20 billion in a single week to acquire biotech firms with approved products or promising pipelines, accounting for three of the year’s four largest deals. Merck bought Terns Pharmaceuticals for $6.7 billion, while...
Ambrosia Biosciences announced the completion of a $100 million Series B financing round to fund the development of next‑generation small‑molecule GLP‑1 oral therapies for obesity. The capital will support a Phase 1 trial of its lead GLP‑1 candidate, which leverages AI‑driven molecular design...
A coalition of nearly 100 rare‑disease patient groups, biotech executives and investors wrote to President Trump, Health Secretary Robert F. Kennedy Jr., Medicare administrator Mehmet Oz and FDA Commissioner Marty Makary urging the administration to restore regulatory clarity at the...
A recent proof‑of‑concept study introduces DNA‑drug conjugates (DDCs) that turn “smart drugs” into programmable therapies. DDCs use split DNA strands as logic gates to release payloads only when specific biomarker combinations are present, offering higher specificity than antibody‑drug conjugates (ADCs)....
Axsome Therapeutics has signed an asset purchase agreement with Takeda to acquire worldwide rights to the PDE10A inhibitor TAK‑063, branded as balipodect. The deal provides Axsome with the ability to develop, manufacture and commercialize the drug for schizophrenia and Tourette...
A cross‑sectional analysis of 19,862 Chinese adults linked elevated LDL‑C to higher glucose, BMI, blood pressure, white‑blood‑cell count and triglycerides, especially among middle‑aged and older men. Parallel in‑vitro experiments showed native LDL directly impairs H9C2 cardiomyocyte viability, proliferation, migration and...
Estonian compliance startup Validfor secured a $1.2 million pre‑seed round led by DOMiNO Ventures, with participation from Curiosity VC and angels. The company is building an AI‑native, agentic digital validation platform that promises to shrink pharma, biotech and medtech validation cycles...
Danish biotech IO Biotech announced it will wind down operations and file for Chapter 7 bankruptcy after regulatory setbacks. The FDA rejected its biologics license application for the cancer vaccine Cylembio in September, citing insufficient data. A Phase 3 trial combining Cylembio...
The European Medicines Agency has released a draft qualification opinion that would allow virtual control groups (VCGs) to replace rats in dose‑range‑finding toxicology studies. The proposal, submitted by Synapse Research and five pharma partners under the VICT3R consortium, is open...
A novel glioblastoma treatment combining oral 5‑ALA with low‑intensity ultrasound has shown promising early results, extending median survival by over 14 months in a phase 1 trial for recurrent patients. The approach sensitizes tumor cells to ultrasound, allowing diffuse targeting of...
In this DDW podcast episode, host Bruno Quinney discusses two recent DDW articles: one on the urgent need to combat antimicrobial resistance (AMR) with insights from Professor Janet Hemingway, and another on the rapid expansion of mRNA therapeutics. Hemingway highlights...
Today @theA4LI is at the New Hampshire State House supporting HB 1734 and HB 1735, two bills that would license experimental treatment centers and expand Right to Try protections to patients with severe illness, not just terminal conditions. As a longevity...
GlaxoSmithKline’s biologic Exdensur (depemokimab) received approval from China’s National Medical Products Administration as an add‑on maintenance therapy for patients aged 12 and older with severe eosinophilic asthma. The approval is based on Phase III SWIFT‑1 (382 participants) and SWIFT‑2 (380 participants)...
The biotech sector is witnessing a wave of collaborations and product launches aimed at accelerating drug discovery and expanding genomic knowledge. Biotium introduced the ViaPlex™ 2‑Color Cell Barcoding Kit, enabling multiplex analysis of up to 15 cell populations in a...
Oric Pharmaceuticals announced that its PRC2 inhibitor will move into a registrational Phase 3 trial for prostate cancer after reporting encouraging safety and disease‑control signals in a Phase 1b study. The company plans to evaluate the drug both as a...
Frontier Medicines has granted LG Chem an exclusive global license to develop and commercialize its covalent p53 Y220C activator FMC-220 outside Greater China, while retaining full rights within that region. LG Chem will manage regulatory filings, global clinical development, and...
MyGevity announced the nationwide launch of a precision‑health platform that links at‑home genetic testing to real‑time lab diagnostics through Quest Diagnostics. The service combines DNA analysis, epigenetic age scoring and continuous biomarker monitoring, delivering personalized recommendations and a dedicated genomics...
The U.S. Food and Drug Administration granted accelerated approval to Denali Therapeutics' intravenous enzyme replacement therapy Avlayah, marking the first new treatment for Hunter syndrome in two decades. The approval could extend lives and curb cognitive decline for the roughly...
Rhythm Pharmaceuticals saw its shares rise 12.58% after the FDA approved Imcivree for acquired hypothalamic obesity, expanding the drug’s addressable U.S. market by 10,000 patients. The move follows a 46% revenue jump to $189.8 million in 2025 but comes amid recent...
Hugel Inc. signed a distribution deal with Hans Biomed to sell the ECM‑based injectable CellREDM™ in South Korea, marking the company's first partnership on a third‑party product and a push to broaden its B2B aesthetic offerings.
Ultragenyx Pharmaceutical reported that its Phase 3 Enh3ance trial of DTX301, an AAV8 gene therapy for ornithine transcarbamylase deficiency, achieved an 18% reduction in 24‑hour plasma ammonia versus placebo at Week 36, with average ammonia levels staying within normal range. Eight of...
Oppenheimer kept an Outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110, signaling a potential upside of more than 166%. Wells Fargo trimmed its target slightly to $110 while remaining Overweight. Both firms highlighted a slower‑than‑expected...
Mineralys Therapeutics (NASDAQ:MLYS) received a renewed Buy rating from Bank of America Securities, which lifted its price target to $51 from $46 after the company reported fourth‑quarter results. The firm highlighted progress on lorundrostat, an aldosterone synthase inhibitor, noting the...
AMSBIO introduced RPMotion, a spinning organoid bioreactor that accelerates and automates 3‑D cell culture for drug discovery, disease modeling and regenerative medicine. The system delivers up to five‑fold faster organoid expansion while cutting reagent costs by roughly 60% and labor...
Berlin’s biotech sector is gaining global traction, highlighted by six innovative firms. 3B Pharmaceuticals secured a Novartis licensing deal for its FAP‑2286 radioligand and is collaborating on an astatine‑211 candidate. Ariceum Therapeutics dosed its first patient in a phase 1/2 trial...
Researchers have created a conductive hydrogel, PEDOT:sGAGh, that mimics the extracellular matrix while sensing oxygen and electrically regulating growth‑factor release. By polymerizing less than 1 wt % PEDOT within a sulfated glycosaminoglycan hydrogel, they achieved a 95 wt % water‑rich, soft material with dual...
Boston Scientific announced FDA 510(k) clearance for its Asurys Fluid Management System, a device that provides automated irrigation and intrarenal pressure control during endoscopic urologic procedures such as ureteroscopy. The system integrates with the LithoVue Elite single‑use digital ureteroscope, allowing...
STAT’s quarterly biotech scorecard lists 23 upcoming events that could move biotech stocks in Q2 2026. Highlights include Phase 3 results from Abivax’s obefazimod in ulcerative colitis and Allogene Therapeutics’ interim data on its cema‑cel CAR‑T therapy for B‑cell lymphoma. The...
Elidah announced that the U.S. Food and Drug Administration has cleared its at‑home device, Elitone for Men, to treat urinary incontinence after prostate surgery. The non‑invasive system delivers neuromuscular stimulation to the pelvic floor for a 20‑minute daily session, eliminating...
Biopharma R&D careers are shifting from title‑driven ladders to skills‑centric portfolios as AI automates routine tasks. Professionals must treat each role as an opportunity to acquire execution‑level capabilities, use generative AI to deepen scientific judgment, and continuously assess and market...
Radiotherapeutics have moved from niche concepts to a burgeoning oncology platform, driven by unmet treatment gaps and the commercial breakthrough of Novartis' Pluvicto. Early data show Actinium‑225 delivering 45‑50% response rates in heavily pre‑treated prostate cancer, while Bayer's Xofigo adds...
AskBio, a Bayer subsidiary, announced that enrollment for its GenePHIT Phase 2 trial of the investigational gene therapy AB‑1002 has been completed, randomizing 173 patients with non‑ischemic cardiomyopathy and NYHA Class III heart‑failure symptoms. The trial, spanning 46 sites across North America...
Camille Bouget, CEO and co‑founder of Scienta Lab, launched EVA, a multimodal AI platform designed to accelerate immunology drug development. The model helps R&D teams identify viable therapeutic targets, predict preclinical efficacy, and stratify patients for clinical trials. By applying...
A team of scholars led by Steve Calandrillo proposes that FDA and IRBs adopt fair‑market‑value (FMV) payments for the data participants generate in clinical trials. Currently, participants receive modest compensation—about $4,000 per year—solely for trial involvement, not for the valuable...
Novo Nordisk $NVO obesity drug Wegovy will be an option for about 1.2 million more patients in England’s National Health Service - Bloomberg
This tweet and accompanying paper are fairly misleading (note: paper is from July ‘24) There are many issues w the study itself that it’s a bit tough to go into here. But most importantly, the paper concludes: “Our findings support the...
Lantern Pharma Inc. posted a narrower fourth‑quarter net loss and saw its stock rise 26.3% to $1.56. The company also confirmed a mid‑May 2026 FDA Type C meeting for LP‑300, its phase‑2 lung‑cancer therapy, underscoring a pivotal regulatory milestone for...
1/🚨@CaribouBio announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 - $CRBU allogeneic anti-BCMA CAR-T Cell Therapy for treating relapsed or refractory multiple myeloma (r/r MM) cancer which is being evaluated in the CaMMouflage...
Paragon launched its 7th company today -- Korsana Biosciences, merging into the $CYCN public shell. New ticker will be $KRSA. Lead drug candidate is a shuttled anti-amyloid beta antibody for Alzheimer's disease in early studies. https://t.co/RcJ8adMakm
Scholar Rock Holding Corp. resubmitted its Biologics License Application for apitegromab to the FDA, adding a second U.S. fill‑finish site to secure supply. The move lifted the shares about 11% in early trading and positions the company for a PDUFA...
Eli Lilly bet $2.75B on AI drug discovery. Best AI model in the world: 0.37% on a reasoning benchmark. Both facts are true simultaneously. Vertical AI that knows your domain: already working. General AI that reasons universally: still finding its ceiling. https://t.co/7iTOUGavT3
Vibing some more on my in-terminal plasmid editor. Drafting a parts bin that's aesthetically pleasing but also functional. TUI's are wonderful. https://t.co/yu8WUSLgwA
Eli Lilly agreed to buy Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash plus a contingent value right worth up to $9 per share. The announcement lifted Centessa’s Nasdaq price 45% to a 52‑week high, underscoring...
Adiponectin and aging: Mechanistic insights, clinical paradox, and therapeutic horizons "Adiponectin has been implicated in aging and the onset of age-related disease.... Adiponectin signaling protects multiple tissues from age-associated decline... Adiponectin signaling agonists as therapeutics in metabolic and age-related disease." https://t.co/9NcjtjlbjR
Implantable islet cells could control diabetes without insulin injections by Anne Trafton @MIT Learn more: https://t.co/aPCxukXMW1 #MedTech #HealthTech #Tech #TechForGood https://t.co/hXbxvs5HTM
Aubrey de Grey, founder and CSO of the Longevity Escape Velocity Foundation, told listeners of Longevity Technology Unlocked that emerging therapies could rejuvenate people in their 60s back to a biological age of 40, buying roughly 20 years for further...
Proud to announce that @NineDiagnostics has been selected for Spring 2026 @SCbio × @MassBio Drive — #biomarkers & #diagnostics track 🎉 One of 11 selected companies. We're focused on building AI-enabled tools to redefine earlier cancer detection and treatment decisions....
